Literature DB >> 10095106

TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line.

Z Duan1, A J Feller, H C Toh, T Makastorsis, M V Seiden.   

Abstract

The mechanisms responsible for the development of the taxol resistance phenotype are unclear, and are likely explained by multiple mechanisms. To understand the molecular changes associated with drug resistance more fully, a taxol-resistant subline, derived from the human ovarian cancer cell line SKOV-3, was established through selection by culture in incrementally increasing taxol concentrations. Comparison of SKOV-3 to SKOV-3TR by differential display identifies a new gene, TRAG-3 (Taxol Resistance Associated Gene- 3). In comparison to the parental line, SKOV-3, TRAG-3 mRNA is overexpressed in the taxol-resistant cell line SKOV-3TR. The nucleotide sequence of the TRAG-3 cDNA contains an open reading frame of 333bp that predicts for a protein product of 110 amino acids. A GenBank search identifies a cosmid clone containing a genomic sequence corresponding to that of TRAG-3. DNA and protein analysis reveals that TRAG-3 has no homology to any known cDNAs or proteins. Northern analysis demonstrates that TRAG-3 is overexpressed in the taxol-resistant breast cancer cell line MDA 435TR as well as the doxorubicin-resistant multiple myeloma cell lines 8226/DOX40 and 8226/MDR10V. A survey of normal tissue shows minimal or absent TRAG-3 mRNA expression. Screening of a wide variety of cancer cell lines demonstrates TRAG-3 expression in many cell lines derived from different tissue types. In summary, TRAG-3 is a novel gene whose expression is associated with the chemotherapy-resistant and neoplastic phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10095106     DOI: 10.1016/s0378-1119(99)00042-6

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  24 in total

Review 1.  Molecular genetics of ovarian cancer.

Authors:  A N Shelling; W Foulkes
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

2.  Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.

Authors:  Robert Cornelison; Zachary C Dobbin; Ashwini A Katre; Dae Hoon Jeong; Yinfeng Zhang; Dongquan Chen; Yuliya Petrova; Danielle C Llaneza; Adam D Steg; Laura Parsons; David A Schneider; Charles N Landen
Journal:  Clin Cancer Res       Date:  2017-08-04       Impact factor: 12.531

3.  Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

Authors:  Adam D Steg; Ashwini A Katre; Blake Goodman; Hee-Dong Han; Alpa M Nick; Rebecca L Stone; Robert L Coleman; Ronald D Alvarez; Gabriel Lopez-Berestein; Anil K Sood; Charles N Landen
Journal:  Clin Cancer Res       Date:  2011-07-13       Impact factor: 12.531

Review 4.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

5.  Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours.

Authors:  Pavel S Yarmolenko; Yulin Zhao; Chelsea Landon; Ivan Spasojevic; Fan Yuan; David Needham; Benjamin L Viglianti; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

6.  Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients.

Authors:  Verena Materna; Paweł Surowiak; Irina Kaplenko; Merek Spaczyński; Zhenfeng Duan; Maciej Zabel; Manfred Dietel; Hermann Lage
Journal:  Virchows Arch       Date:  2007-02       Impact factor: 4.064

7.  Upregulation of TRAG3 gene in urothelial carcinoma of the bladder.

Authors:  Jose A Karam; Sandra Huang; Jinhai Fan; Jennifer Stanfield; Roger A Schultz; Rey-Chen Pong; Xiankai Sun; Ralph P Mason; Xian-Jin Xie; Gang Niu; Xiaoyuan Chen; Eugene P Frenkel; Arthur I Sagalowsky; Jer-Tsong Hsieh
Journal:  Int J Cancer       Date:  2010-10-26       Impact factor: 7.396

8.  NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.

Authors:  Zhenfeng Duan; Edwin Choy; Francis J Hornicek
Journal:  PLoS One       Date:  2009-10-12       Impact factor: 3.240

9.  ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.

Authors:  Zhenfeng Duan; Edwin Choy; David Harmon; Cao Yang; Keinosuke Ryu; Joseph Schwab; Henry Mankin; Francis J Hornicek
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

10.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.